Kinetics of Epstein-Barr Virus (EBV) Neutralizing and Virus-Specific Antibodies After Primary Infection with EBV

Overview

Journal Clin Vaccine Immunol

Publisher American Society for Microbiology

Specialties Allergy & Immunology
Pathology

Date 2016 Feb 19

PMID 26888186

Citations 26

Authors

Wei Bu

Gregory M Hayes

Hui Liu

Lorraine Gemmell

David O Schmeling

Pierce Radecki

Fiona Aguilar

Peter D Burbelo

Jennifer Woo

Henry H Balfour Jr

Jeffrey I Cohen

Affiliations

Soon will be listed here.

Abstract

Prospective studies of antibodies to multiple Epstein-Barr virus (EBV) proteins and EBV neutralizing antibodies in the same individuals before, during, and after primary EBV infection have not been reported. We studied antibody responses to EBV in college students who acquired primary EBV infection during prospective surveillance and correlated the kinetics of antibody response with the severity of disease. Neutralizing antibodies and enzyme-linked immunosorbent assay (ELISA) antibodies to gp350, the major target of neutralizing antibody, reached peak levels at medians of 179 and 333 days after the onset of symptoms of infectious mononucleosis, respectively. No clear correlation was found between the severity of the symptoms of infectious mononucleosis and the peak levels of antibody to individual viral proteins or to neutralizing antibody. In summary, we found that titers of neutralizing antibody and antibodies to multiple EBV proteins increase over many months after primary infection with EBV.

Citing Articles

High IgG titers against EBV glycoprotein 42 correlate with lower risk of nasopharyngeal carcinoma.

Warner B, Shair K J Clin Invest. 2025; 135(4).

PMID: 39959976 PMC: 11827836. DOI: 10.1172/JCI189207.

Research landmarks on the 60th anniversary of Epstein-Barr virus.

Zhong L, Xie C, Zhang L, Yang Y, Liu Y, Zhao G Sci China Life Sci. 2024; 68(2):354-380.

PMID: 39505801 DOI: 10.1007/s11427-024-2766-0.

TianTan vaccinia virus-based EBV vaccines targeting both latent and lytic antigens elicits potent immunity against lethal EBV challenge in humanized mice.

Zhang X, Chen Y, Wang S, Zhong L, Xiang Z, Zhang X Emerg Microbes Infect. 2024; 13(1):2412640.

PMID: 39387189 PMC: 11485817. DOI: 10.1080/22221751.2024.2412640.

Epstein-Barr virus reactivation is not causative for post-COVID-19-syndrome in individuals with asymptomatic or mild SARS-CoV-2 disease course.

Hoeggerl A, Nunhofer V, Lauth W, Badstuber N, Held N, Zimmermann G BMC Infect Dis. 2023; 23(1):800.

PMID: 37968601 PMC: 10652630. DOI: 10.1186/s12879-023-08820-w.

Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to EBV in HLA-expressing mice.

Dasari V, McNeil L, Beckett K, Solomon M, Ambalathingal G, Thuy T Nat Commun. 2023; 14(1):4371.

PMID: 37553346 PMC: 10409721. DOI: 10.1038/s41467-023-39770-1.

References

Goldstein K, Lai P, Lightfoote M, Andrese A, Fuccillo D, Connor R . Relationship of in vitro immune responses to Epstein-Barr herpesvirus and severity of infectious mononucleosis. Infect Immun. 1980; 29(3):945-52. PMC: 551222. DOI: 10.1128/iai.29.3.945-952.1980. View

Hewetson J, Rocchi G, Henle W, Henle G . Neutralizing antibodies to Epstein-Barr virus in healthy populations and patients with infectious mononucleosis. J Infect Dis. 1973; 128(3):283-9. DOI: 10.1093/infdis/128.3.283. View

Thorley-Lawson D, Poodry C . Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo. J Virol. 1982; 43(2):730-6. PMC: 256176. DOI: 10.1128/JVI.43.2.730-736.1982. View

Horwitz C, Henle W, Henle G, RUDNICK H, Latts E . Long-term serological follow-up of patients for Epstein-Barr virus after recovery from infectious mononucleosis. J Infect Dis. 1985; 151(6):1150-3. DOI: 10.1093/infdis/151.6.1150. View

Henle W, Henle G, Andersson J, Ernberg I, Klein G, Horwitz C . Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection. Proc Natl Acad Sci U S A. 1987; 84(2):570-4. PMC: 304252. DOI: 10.1073/pnas.84.2.570. View

Hille A, Klein K, Baumler S, Grasser F, Mueller-Lantzsch N . Expression of Epstein-Barr virus nuclear antigen 1,2A and 2B in the baculovirus expression system: serological evaluation of human antibodies to these proteins. J Med Virol. 1993; 39(3):233-41. DOI: 10.1002/jmv.1890390311. View

Jackman W, Mann K, Hoffmann H, Spaete R . Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine. Vaccine. 1999; 17(7-8):660-8. DOI: 10.1016/s0264-410x(98)00248-5. View

Balfour Jr H, Holman C, Hokanson K, Lelonek M, Giesbrecht J, White D . A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis. J Infect Dis. 2005; 192(9):1505-12. DOI: 10.1086/491740. View

Cameron B, Bharadwaj M, Burrows J, Fazou C, Wakefield D, Hickie I . Prolonged illness after infectious mononucleosis is associated with altered immunity but not with increased viral load. J Infect Dis. 2006; 193(5):664-71. DOI: 10.1086/500248. View

10.

Moutschen M, Leonard P, Sokal E, Smets F, Haumont M, Mazzu P . Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. Vaccine. 2007; 25(24):4697-705. DOI: 10.1016/j.vaccine.2007.04.008. View

11.

Sokal E, Hoppenbrouwers K, Vandermeulen C, Moutschen M, Leonard P, Moreels A . Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis. 2008; 196(12):1749-53. DOI: 10.1086/523813. View

12.

Heller K, Arrey F, Steinherz P, Portlock C, Chadburn A, Kelly K . Patients with Epstein Barr virus-positive lymphomas have decreased CD4(+) T-cell responses to the viral nuclear antigen 1. Int J Cancer. 2008; 123(12):2824-31. PMC: 2605183. DOI: 10.1002/ijc.23845. View

13.

Sashihara J, Burbelo P, Savoldo B, Pierson T, Cohen J . Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay. Virology. 2009; 391(2):249-56. PMC: 2728425. DOI: 10.1016/j.virol.2009.06.013. View

14.

Burbelo P, Bren K, Ching K, Gogineni E, Kottilil S, Cohen J . LIPS arrays for simultaneous detection of antibodies against partial and whole proteomes of HCV, HIV and EBV. Mol Biosyst. 2011; 7(5):1453-62. PMC: 3430135. DOI: 10.1039/c0mb00342e. View

15.

Balfour Jr H, Odumade O, Schmeling D, Mullan B, Ed J, Knight J . Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students. J Infect Dis. 2012; 207(1):80-8. PMC: 3523797. DOI: 10.1093/infdis/jis646. View

16.

Long H, Chagoury O, Leese A, Ryan G, James E, Morton L . MHC II tetramers visualize human CD4+ T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response. J Exp Med. 2013; 210(5):933-49. PMC: 3646497. DOI: 10.1084/jem.20121437. View

17.

Rickinson A, Long H, Palendira U, Munz C, Hislop A . Cellular immune controls over Epstein-Barr virus infection: new lessons from the clinic and the laboratory. Trends Immunol. 2014; 35(4):159-69. DOI: 10.1016/j.it.2014.01.003. View

18.

Panikkar A, Smith C, Hislop A, Tellam N, Dasari V, Hogquist K . Impaired Epstein-Barr Virus-Specific Neutralizing Antibody Response during Acute Infectious Mononucleosis Is Coincident with Global B-Cell Dysfunction. J Virol. 2015; 89(17):9137-41. PMC: 4524077. DOI: 10.1128/JVI.01293-15. View

19.

Kanekiyo M, Bu W, Joyce M, Meng G, Whittle J, Baxa U . Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site. Cell. 2015; 162(5):1090-100. PMC: 4757492. DOI: 10.1016/j.cell.2015.07.043. View

20.

Cohen J . Primary Immunodeficiencies Associated with EBV Disease. Curr Top Microbiol Immunol. 2015; 390(Pt 1):241-65. PMC: 6349415. DOI: 10.1007/978-3-319-22822-8_10. View